Subsequently, other clinical trials were performed, which showed that ARDS patients with increased levels of transforming growth factor beta 1 (TGF-β1) and procollagen type III had extremely high mortality rates [9–11] than those with lower levels. This evidence concerns the gene TGFB1 and acute respiratory distress syndrome.